Efficacy and Lipid Profile Change after Switching from Efavirenz to Rilpivirine
Article Sidebar
Published:
Dec 31, 2018
Keywords:
Efavirenz Rilpivirine Lipid profile
Main Article Content
Abstract
Efavirenz is Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) which is associated with central nervous system adverse events (e.g. confusion and nightmare). Long-term use of efavirenz is associated with lipid profile abnormalities. Both efavirenz and rilpivirine belong to the NNRTI class of antiretrovirals but the overall incidence of adverse events was lower in rilpivirine than efavirenz. The aim of this study was to compare change in lipid profiles after switched from efavirenz to rilpivirine. After switching treatment, lipid profile trend to decrease LDL-C 15.87 mg/dl (95%CI: -24.57 to -7.17), triglyceride 31.25 mg/dl (95%CI: -46.75 to -15.75), total cholesterol 27.27 mg/dl (95%CI: -38.74 to -15.81) and HDL-C 5.75 mg/dl (95%CI: -8.58 to -2.92). Lipid profile improved after switching regimen.
Article Details
How to Cite
สมตน ป., & สุธนนันท์ ว. (2018). Efficacy and Lipid Profile Change after Switching from Efavirenz to Rilpivirine. Journal of Bamrasnaradura Infectious Diseases Institute, 12(3), 105–111. retrieved from https://he01.tci-thaijo.org/index.php/bamrasjournal/article/view/185725
Section
Original Articles
References
1. Fauci AS, Folkers GK, Lane HC. Human Immuno-deficiency Virus Disease: AIDS and related disorders. In: Kasper D, Fauci A, Hauser S, Longo D, Jameson JL, Loscalzo J, editors. Harrison’s principles of internal medicine. 19th ed. NY: McGraw-Hill Education; 2015. p. 1215-85.
2. UNAIDS. Coverage of people receiving ART 2017. [internet]. 2017 [cited 2018 Feb 10].9 p. Available from: http://www.unaids.org/en/regionscountries/countries/thailand
3. Manosuthi W, Chottanapand S, Thongyen S, Chaovavanich A, Sungkanuparph S. Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy. J Acq Immun Def Synd 2006; 43(1): 42-6.
4. Paula AA, Falcäo MCN, Pacheco AG. Metabolic syndrome in HIV-infected individuals: underlying mechanisms and epidemiological aspects. AIDS Res Ther 2013; 10(1): 32. doi: 10. 1186/1742-6405-10-32. PMID: 24330597.
5. Cohen CJ, Molina JM, Cahn P, Clotet B, Fourie J, Grinsztejn B, et al. Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials. J Acq Immun Def Synd 2012; 60(1): 33-42.
6. Behrens G, Rijnders B, Nelson M, Orkin C, Cohen C, Mills A, et al. Rilpivirine versus efavirenz with emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected patients with HIV-1 RNA
7. Mills AM, Cohen C, Dejesus E, Brinson C, Williams S, Yale KL, et al. Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate based single-tablet regimens. HIV Clin Trials 2013; 14(5): 216-23.
8. Tebas P, Sension M, Arribas J, Duiculescu D, Florence E, Hung CC, et al. Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-Infected adults treated with rilpivirine or Efavirenz for 96 weeks in the ECHO and THRIVE trials. Clin Infect Dis 2014; 59(3): 425-34. doi: 10.1093/cid/ciu234. PMID: 24729492.
9. Thamrongwonglert P, Chetchotisakd P, Anunnatsiri S, Mootsikapun P. Improvement of lipid profiles when switching from efavirenz to rilpivirine in HIV-infected patients with dyslipidemia. HIV Clin Trials 2016; 17(1): 12-6.
10. Troya J, Ryan P, Ribera E, Podzamczer D, Hontanon V, Terron JA, et al. Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study. PloS One 2016; 11(10): e0164455. doi: 10.1371/journal.pone.0164455. PMID: 27727331.
11. Taramasso L, Tatarelli P, Ricci E, Madeddu G, Menzaghi B, Squillace N, et al. Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA). BMC Infect Dis 2018; 18(1): 357. doi: 10.1186/s12879-018-3268-5. PMID: 30064371.
2. UNAIDS. Coverage of people receiving ART 2017. [internet]. 2017 [cited 2018 Feb 10].9 p. Available from: http://www.unaids.org/en/regionscountries/countries/thailand
3. Manosuthi W, Chottanapand S, Thongyen S, Chaovavanich A, Sungkanuparph S. Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy. J Acq Immun Def Synd 2006; 43(1): 42-6.
4. Paula AA, Falcäo MCN, Pacheco AG. Metabolic syndrome in HIV-infected individuals: underlying mechanisms and epidemiological aspects. AIDS Res Ther 2013; 10(1): 32. doi: 10. 1186/1742-6405-10-32. PMID: 24330597.
5. Cohen CJ, Molina JM, Cahn P, Clotet B, Fourie J, Grinsztejn B, et al. Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials. J Acq Immun Def Synd 2012; 60(1): 33-42.
6. Behrens G, Rijnders B, Nelson M, Orkin C, Cohen C, Mills A, et al. Rilpivirine versus efavirenz with emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected patients with HIV-1 RNA
7. Mills AM, Cohen C, Dejesus E, Brinson C, Williams S, Yale KL, et al. Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate based single-tablet regimens. HIV Clin Trials 2013; 14(5): 216-23.
8. Tebas P, Sension M, Arribas J, Duiculescu D, Florence E, Hung CC, et al. Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-Infected adults treated with rilpivirine or Efavirenz for 96 weeks in the ECHO and THRIVE trials. Clin Infect Dis 2014; 59(3): 425-34. doi: 10.1093/cid/ciu234. PMID: 24729492.
9. Thamrongwonglert P, Chetchotisakd P, Anunnatsiri S, Mootsikapun P. Improvement of lipid profiles when switching from efavirenz to rilpivirine in HIV-infected patients with dyslipidemia. HIV Clin Trials 2016; 17(1): 12-6.
10. Troya J, Ryan P, Ribera E, Podzamczer D, Hontanon V, Terron JA, et al. Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study. PloS One 2016; 11(10): e0164455. doi: 10.1371/journal.pone.0164455. PMID: 27727331.
11. Taramasso L, Tatarelli P, Ricci E, Madeddu G, Menzaghi B, Squillace N, et al. Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA). BMC Infect Dis 2018; 18(1): 357. doi: 10.1186/s12879-018-3268-5. PMID: 30064371.
